Baba Kilindi Iyi

Like

0

0

0

0

0

0

0

or copy the link

In our latest Trade To Black Podcast, we recap our conversation earlier this week with Christian Angermayer, Founder & Chairman of atai Life Sciences (NASDAQ: ATAI). Angermayer shared insights on the recent FDA announcement declining approval of novel MDMA therapy for treating PTSD, as submitted by Lykos Therapeutics.

Angermayer expressed no concerns about the future of the psychedelic industry, stating that ongoing trials could lead to the emergence of $20 billion market cap companies. We also receive an update on Big Pharma’s perspective on the industry and discuss the potential for more industry executives to enter the space as trials progress.

Additionally, Angermayer shares his experience being featured on the Joe Rogan Experience podcast and discusses what the podcast host learned from their conversation.

Here is the latest.
#joerogan #mdma #psychedelics #ibogaine #mentalhealth #atailifesciences

Want to see more videos about Biotech?
https://www.youtube.com/watch?v=2PwMfYe8iAQ
https://www.youtube.com/watch?v=J3-3HHv8on8
https://www.youtube.com/watch?v=I-B4dkXfIz4
https://www.youtube.com/watch?v=gzSJ5f1pLrQ

Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!
https://newsletter.thedalesreport.com/subscribe

Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:
Facebook: https://www.facebook.com/TheDalesReport
Twitter: https://twitter.com/TheDalesReport
Instagram: https://www.instagram.com/dalesreport
Website: https://thedalesreport.com/

For copyright matters, please get in touch with us at:
sdales@thedalesreport.com

All views on the Trade To Black podcast and the guests on this podcast are purely opinions. You should not treat any opinions expressed by us or our guests as investment advice. The views on this podcast are solely intended to be informational and are not investment advice. Please go to our website for a full list of disclosures and details of any client relationship we have.
https://thedalesreport.com/website-terms-of-use/

Comments

@luisalberto7573 says:

September 15, 2024 at 8:39 am

Did he really say atai will be a 20b company ? If he did he lost my credability

Reply

@jake3028 says:

September 15, 2024 at 9:04 am

Important to note about spravato: Patients need to come in twice a week for the first 4 weeks of treatment, then once every week or 2 for maintenance. Short acting psychedelics may only require 2-4 treatments a year (although licensed therapists will most likely be required).

Big readouts this year/early next year……

Reply